Patents Examined by Rita J. Desai
  • Patent number: 10494377
    Abstract: A compound having the formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.
    Type: Grant
    Filed: September 3, 2018
    Date of Patent: December 3, 2019
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Bin Tian, Xingke Ju, Lei Tian, Jie Li, Songsong Ruan, Minyi Jia, Danni Tian, Han Li, Qianqian Zhao, Xuechuan Wang, Chengyuan Liang
  • Patent number: 10487083
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: November 26, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Russell C. Smith, Mark S. Tichenor, Aihua Wang
  • Patent number: 10487094
    Abstract: A compound having the following formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.
    Type: Grant
    Filed: September 3, 2018
    Date of Patent: November 26, 2019
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Chengyuan Liang, Yuzhi Liu, Danni Tian, Jie Li, Songsong Ruan, Han Li, Qianqian Zhao, Xuechuan Wang, Xeufeng Chen
  • Patent number: 10472355
    Abstract: An SP-141 compound is a novel small molecule that can serve as a molecular-targeted chemotherapeutic agent. In one embodiment, the labeled compound can comprise SP-141, which comprises 6-methoxy-1-(naphthalen-1-yl)-9 H-pyrido[3,4-b]indote. The compound inhibits expression of oncogenes such as the Mouse Double Minute 2 protein. The compound can bind directly to Mouse Double Minute 2 to inhibit cancer growth including breast cancer growth.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: November 12, 2019
    Assignee: Texas Tech University System
    Inventors: Ruiwen Zhang, Wei Wang
  • Patent number: 10472351
    Abstract: The present technology is directed to modulators of nuclear receptor activity, specifically to the modulation of NR2F6 activity and NR2F6 utilizing compounds, and the immune modulation and modulation of cancer stem cell activity through administration of compounds described herein to animals.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: November 12, 2019
    Assignee: Zander Therapeutics, Inc.
    Inventors: Harry M. Lander, David R. Koos
  • Patent number: 10472361
    Abstract: Compounds having a structure according to formula (I) where R1, R2, and R3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: November 12, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar, Prasanna Sivaprakasam, Shoshana L. Posy
  • Patent number: 10464919
    Abstract: The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against PARP-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against PARP-1, tankyrase-1, or tankyrase-2, and thus can be effectively used for the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, or cancer.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: November 5, 2019
    Assignee: Je Il Pharmaceutical Co., Ltd.
    Inventors: Hyunho Lee, Kwangwoo Chun, Bo-Young Joe, Eun Seon Kim, Eun Sung Jang, Hyeongchan Oh, Jeong-Min Kim, Jiseon Park, Hanchang Lee
  • Patent number: 10457671
    Abstract: The invention relates to a new crystalline form of Canagliflozin of formula I, with its systematic name (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl) methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol5 and a method of its preparation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: October 29, 2019
    Assignee: Zentiva k.s.
    Inventors: Josef Zezula, Peter Babiak, Ondrej Dammer
  • Patent number: 10457643
    Abstract: The invention provides (1) processes for making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; (2) compositions useful in making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 29, 2019
    Assignee: YALE UNIVERSITY
    Inventors: Seth Herzon, Maung Kyaw Moe Tun
  • Patent number: 10450325
    Abstract: This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: as well as new forms of the inhibitor.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 22, 2019
    Assignee: Incyte Corporation
    Inventors: Jiacheng Zhou, Zhongjiang Jia
  • Patent number: 10450288
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
  • Patent number: 10435564
    Abstract: Provided is a compound capable of exhibiting different changes in hue with one kind of molecule. The compound has julolidine structures, and is represented by a general formula (1): wherein each of Q and Q1 represents C(R) or N; R represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, or a carboxyl group, where two Rs may bind to each other to form a ring; R1 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, or a carboxyl group, where two R1s may bind to each other to form a ring; n represents a number of 0 to 3; and m represents a number of 0 to 3.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: October 8, 2019
    Assignee: RIKEN
    Inventors: Atsuya Muranaka, Yoshinao Shirasaki, Masanobu Uchiyama, Shinichiro Kamino
  • Patent number: 10428034
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 1, 2019
    Assignee: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Laura Ann McAllister, Elizabeth Mary Beck, Michael Aaron Brodney, Adam Matthew Gilbert, Christopher John Helal, Douglas Scott Johnson, Justin Ian Montgomery, Steven Victor O'Neil, Bruce Nelsen Rogers, Patrick Robert Verhoest, Damien Webb
  • Patent number: 10428088
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X1, X2, R1, R2, R3 and R4 are as defined herein.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 1, 2019
    Assignee: Heptares Therapeutics Limited
    Inventors: Miles Stuart Congreve, Giles Albert Brown, Benjamin Gerald Tehan, Mark Pickworth, Julie Elaine Cansfield
  • Patent number: 10399968
    Abstract: Problem to be Solved There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. Solution to the Problem As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: September 3, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Manoj Kumar Khera, Tarun Mathur, Jitendra A. Sattigeri, Nobuhisa Masuda, Tsuyoshi Soneda, Yoshiko Kagoshima, Toshiyuki Konosu, Tetsuya Suzuki, Makoto Yamaoka, Ryo Itooka
  • Patent number: 10392385
    Abstract: A compound of general formula A, useful as potential anticancer agents against human cancer cell lines and process for the preparation thereof. General formula A R1=3-F, 3,4,5-OMe, 4-OMe, H, 4-CF3, 4-Cl, 4-OH-3-OMe, 3,4-CH2—O—CH2, 3,5-F, 4-OH, 1-napthyl, 9-phenanthryl, 4-Me. R2=3,4,5-OMe, 3,4-Cl, 4-F, 3,5-F, 2,5-OMe, 4-Cl, 4-OH-3-OMe, 3-OH, 3,4,5-OH, 4-CF3, 4-OMe, 4-NH2.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 27, 2019
    Assignee: Council of Scientific & Industrial Research
    Inventors: Ahmed Kamal, Sathish Manda, Nagesh Narayana, Shankaraiah Nagula, Chetan Dushantrao Sabanis, Hari Krishna Namballa
  • Patent number: 10385070
    Abstract: The invention relates to chroman spirocyclic piperidine amide derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: August 20, 2019
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Sara Sabina Hadida-Ruah, Mark Thomas Miller, Edward Adam Kallel, Brian Richard Bear, Vijayalaksmi Arumugam, Michael Paul Deninno, Jinglan Zhou, Johnny Uy, Bryan A. Frieman
  • Patent number: 10377750
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: August 13, 2019
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Peter James Lindsay-Scott, Richard Edmund Rathmell
  • Patent number: 10370375
    Abstract: The invention relates to a compound of formula (I) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (I) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis. Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, Crohn's disease, Alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: August 6, 2019
    Assignee: Elanco Tiergesundheit AG
    Inventors: Noelle Gauvry, Chouaib Tahtaoui, Pascal Furet, Pierre Ducray
  • Patent number: 10364246
    Abstract: 2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: July 30, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tatiana Koudriakova, Kevin D. Kreutter, Kristi Leonard, Michele C. Rizzolio, Russell C. Smith, Mark S. Tichenor, Aihua Wang